Clinical trial
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
NCT00442169 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00442169 |
|---|---|
| Title | Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults |
| Official title | Randomized, Double-blind, Placebo Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Lyophilized ChimeriVax-WN02 West Nile Vaccine in Healthy Adults |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | West Nile Fever |
| Intervention type | Biological |
| Interventions | ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution |
| Enrollment | 208 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Mar 1, 2007 |
| Last update posted | Apr 14, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: